The association between tumor mutational burden and prognosis is dependent on treatment context
- 4 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Genetics
- Vol. 53 (1), 11-15
- https://doi.org/10.1038/s41588-020-00752-4
Abstract
In multiple cancer types, high tumor mutational burden (TMB) is associated with longer survival after treatment with immune checkpoint inhibitors (ICIs). The association of TMB with survival outside of the immunotherapy context is poorly understood. We analyzed 10,233 patients (80% non-ICI-treated, 20% ICI-treated) with 17 cancer types before/without ICI treatment or after ICI treatment. In non-ICI-treated patients, higher TMB (higher percentile within cancer type) was not associated with better prognosis; in fact, in many cancer types, higher TMB was associated with poorer survival, in contrast to ICI-treated patients in whom higher TMB was associated with longer survival.Keywords
Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health (R01 DE027738)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
- The Jayme and Peter Flowers Fund, the Sebastian Nativo Fund, the Catherine and Frederick Adler Junior Faculty Chair, and Cycle for Survival.
- Fundación Alfonso Martín Escudero
- U.S. Department of Health & Human Services | National Institutes of Health (R01 CA205426, R35 CA232097)
- Pershing Square Sohn Cancer Research Foundation, the PaineWebber Chair, Stand Up To Cancer, and the STARR Cancer Consortium,
This publication has 28 references indexed in Scilit:
- The T cell differentiation landscape is shaped by tumour mutations in lung cancerNature Cancer, 2020
- Cancer-Specific Thresholds Adjust for Whole Exome Sequencing–Based Tumor Mutational Burden DistributionJCO Precision Oncology, 2019
- Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology GroupEuropean Journal of Cancer, 2019
- Tumor mutational load predicts survival after immunotherapy across multiple cancer typesNature Genetics, 2019
- Clinical Impact of Tumor Mutational Burden in NeuroblastomaJNCI Journal of the National Cancer Institute, 2018
- Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non–Small Cell Lung Cancer: Brief ReportJournal of Thoracic Oncology, 2018
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience, 2017
- Genomic correlates of response to CTLA-4 blockade in metastatic melanomaScience, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaThe New England Journal of Medicine, 2014